L39 Capital
  • Home
  • AI Biotech Fund
  • About
    • Performance
    • Team
  • Our Approach
    • Our Philosophy
  • Investment Process
  • Our Investments
  • Invest Now
  • Contact

Our 
​Investments

Discover some of our current Listed & Unlisted investments 

Listed  Investments
Picture
Aeeris Ltd (ASX: AER)
Aeeris specialises in the protection of people, property, infrastructure and business operations. They help minimise risk, mitigate natural disaster impacts and manage business interruption threats through a range of multi-channel technology-driven alerting and information services. Their in-house experts provide 24/7, 365 days a year real-time monitoring, and support personnel ensure clients are given timely, relevant and accurate notifications. Click here to learn more
​

Picture
Papyrus Australia (ASX: PPY)
Papyrus Australia is able to convert banana plantation waste, using purely mechanical processes, to produce cost competitive commercial quantities of banana fibre pulp which can be used to produce environmentally friendly moulded food packaging products or for other uses. The process requires no chemicals or water and has a low energy intensity, creating a low emissions product out of planation waste which would otherwise be left to rot and release methane. Click here to learn more
​
Picture
Opyl Ltd (ASX: OPL)
Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Their platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.
Their key offering for biopharma, medtech, government and healthcare organisations are:
  • clinical trial recruitment solutions – Opin.ai
  • clinical trial predictive analytics and protocol design optimisaton – TrialKey.ai

​Unlisted Investments
Picture
Aegros
Aegros HaemaFrac® process uses the mobility of ions in an electric field to transport proteins across a membrane into a collection chamber. This physical arrangement enables the selective isolation of high yield, high purity plasma proteins in rapid time. Click here to learn more
​ 
Picture
EasyPark Australia
EasyPark makes parking simple through its parking app, helping millions of drivers save time and money while eliminating the hassles and stress involved with parking in urban areas. Click here to learn more
​
Picture
Eden Exchange
​Edenexchange.com is an integrated multi-channel platform, simplifying business buying and selling. The platforms matches and connects business buyers & sellers in an ecosystem that facilitates friction-less business and finance transactions. Eden makes it easy to buy and sell a business by improving transaction execution rates though AI, partners' network and a complete suite of deal services, including documentation and financing.  
​
Picture
Imunexus Therapeutics
Imunexus' technology facilitates rapid, cost-effective, lower risk, generation of effective therapeutics by converting existing monoclonal antibodies into multispecifics with additional therapeutic utility.
Their technology will generate a number of potential products for the treatment of a number of cancers, autoimmune and other serious diseases. Click here to learn more
​
Picture
mDetect 
mDetect uses muons (subatomic particles) to provide intelligence on the internal structure of buildings and infrastructure as well as subterranean and submarine features. Built around small, robust and cost-effective devices, mDetect provides the most adaptable and deployable technology platform, revolutionising detection capabilities. Click here to learn more
​
Picture
me&u (Formerly Mr Yum)
The world's most powerful QR code mobile ordering, me&u allows restaurants create a seamless customer experience while growing their sales, data and efficiency. 
me&u is completely web-based, meaning there’s no app for customers to download. Click here to learn more
​
Picture
Cannenta
Cannenta is established to bring affordable, effective advanced wound care products to global markets. In particular it addresses the globally unmet need to promote angiogenesis in chronic wounds using their patented 2dDR. Click here to learn more
T:  +61 415 634 468
E:  [email protected]
Level 1, Suit 7
321 Chapel Street
Prahran, Victoria, 3181
​Australia
© COPYRIGHT 2022 L39 Capital | ABN 94 614 364 117
L39 Capital Pty Ltd (L39) ABN 94 614 364 117 is a Corporate Authorised Representative (CAR #1250323) of Primary Securities Ltd (Primary) ABN 96 089 812 635 AFSL 224107. Primary is the trustee of the L39 Capital fund. L39 is authorised to provide general advice only to wholesale investors. This website is for general informational purposed only and no person(s) circumstances, objectives or needs have been taken into account when preparing this information.
  • Home
  • AI Biotech Fund
  • About
    • Performance
    • Team
  • Our Approach
    • Our Philosophy
  • Investment Process
  • Our Investments
  • Invest Now
  • Contact